THE APEX TIMES
The crypto exchange that currently distributes event contracts through Kalshi is reportedly exploring an in-house alternative to gain more control and potentially a larger share of trading revenue.
Coinbase is reportedly targeting the launch of an in-house prediction markets business by the first half of 2027, moving beyond its current approach of offering event contracts through Kalshi, a specialized prediction market platform. The development, described in a Decrypt report and syndicated by Yahoo Finance, suggests Coinbase wants more direct control over the infrastructure and economics of a fast-growing market niche that sits at the intersection of trading and forecasting.
Prediction markets are structured bets where participants trade contracts tied to real-world outcomes. In practice, this means the market settles based on whether a specific event happens, such as an election result, a regulatory decision, or other measurable outcomes. Event contracts are the tradable instruments in that ecosystem, and exchanges earn revenue from trading activity and related market services.
According to the report, Coinbase already provides access to prediction-market style event contracts via Kalshi. The push to run its own version would represent a shift from being primarily a distributor toward operating the platform itself. That could allow Coinbase to set tighter rules around product design, market creation workflows, and day-to-day risk and compliance operations tied to event-based trading.
The reported motivation is economic as well as operational. By operating the market itself, Coinbase would potentially capture a bigger portion of the revenue associated with prediction-market trading, rather than sharing value with a partner that currently supplies the event-contract offering. The report frames this as a way to increase control over how the product scales and how trading economics are allocated.
Coinbase’s broader position as a large U.S. crypto exchange has brought it into contact with a wider range of regulated financial products and institutional-grade trading tools. Prediction markets, however, are distinct because the contract terms depend on externally determined outcomes, which can raise additional legal, governance, and settlement considerations compared with traditional crypto trading.
Still, the details that investors and industry watchers would likely want are not fully spelled out in the syndicated post. The report does not provide specific information on whether Coinbase plans to build the technology alone, how it would handle any regulatory approvals, or what changes traders and market makers would see in terms of fees, contract formats, or settlement processes relative to the Kalshi-backed model.
Another open question is how Coinbase intends to balance partnership value with platform control. If Coinbase is indeed moving toward an in-house system, the timetable for transitioning liquidity, migrating existing contract listings, and integrating market participants would matter for adoption. The report also does not specify whether the company expects competition in the prediction market segment to change as it enters more directly.
For now, the most concrete takeaway is the timeline and direction of travel: Coinbase appears to be studying or planning a move toward internal operation of prediction markets by the first half of 2027. The next indicates to watch are any official product announcements, regulatory filings or approvals tied to event-contract trading, and updates on whether Coinbase continues to rely on Kalshi as it builds its own platform.
A market-focused note argues the company’s cash-return profile could matter as Wall Street debates whether 2027 can resemble 2022. The company, however, did not provide new disclosure in the cited post.
A market report said the U.S. Securities and Exchange Commission has opened an investigation involving Nvidia as the chipmaker absorbs fallout from a sharp selloff. Investors now have to parse what the agency is looking at and how much the matter could weigh on disclosures and governance.
A reported Phase 3 win for Moderna’s personalized melanoma therapy, used alongside Merck’s Keytruda, is prompting fresh optimism that the mRNA platform can expand beyond infectious disease. Still, key details such as magnitude of benefit and full trial disclosure remain to be validated.
Marques Brownlee said he has placed an order for Tesla’s Cybercab following a 2024 challenge, and Tesla CEO Elon Musk replied “fair enough,” saying he would accept delivery.
A new market read on Booz Allen Hamilton Holding points to a sizable gap between the company’s valuation and the cash flow the business can generate, sharpening questions for investors about how durable profits and cash generation are in the defense IT services market.
The company is pursuing Australian National Immunisation Program listings for its mRNA influenza vaccines after securing a March 2027 agenda spot with the PBAC, a key committee that advises public reimbursement.
A newly announced partnership between Microsoft and Danaher aims to pair AI-assisted capabilities with cloud-based scientific instruments and lab software, including early tools that are already moving toward commercial use.
A new market round-up from Yahoo Finance highlights how lingering discussion among Fed officials about whether interest rates need to rise again can reshape expectations for large, consumer-facing companies like PepsiCo.
The initiative, launched within Aetna, is designed to link a large share of expectant members and their newborns to coordinated maternal and infant care. CVS Health has not, in the reporting, disclosed staffing, clinical protocols, or outcome targets tied to the program.
A fresh round of holiday changes at Target centers on shopping hours and promotions, a shift the company is indicating as part of how it intends to drive demand into the end of the year.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...